Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

65.64EUR
11:35am EDT
Change (% chg)

€3.07 (+4.91%)
Prev Close
€62.57
Open
€62.58
Day's High
€66.96
Day's Low
€62.50
Volume
519,900
Avg. Vol
164,976
52-wk High
€66.96
52-wk Low
€32.90

Latest Key Developments (Source: Significant Developments)

Morphosys: Janssen updates on development of guselkumab
5:33am EDT 

May 24 (Reuters) - MORPHOSYS AG ::ANNOUNCES THAT ITS LICENSEE JANSSEN REPORTED UPDATES ON DEVELOPMENT OF GUSELKUMAB.IN ADDITION, JANSSEN ANNOUNCED PLANS FOR THREE NEW PHASE 3 CLINICAL TRIALS WITH GUSELKUMAB.  Full Article

Morphosys confirms 2017 outlook after Q1 loss widens
Wednesday, 3 May 2017 01:08am EDT 

May 3 (Reuters) - Morphosys Ag :dgap-news: morphosys ag reports solid first quarter 2017.Q1 revenue 11.8 million eur.Group revenues amounted to eur 11.8 million, in line with level of q1 of 2016.Earnings before interest and taxes (ebit) in q1 2017 stood at eur -14.9 million (q1 2016: eur - 9.7 million).In q1 2017, consolidated net result amounted to eur -15.0 million (q1 2016: eur -7.2 million).At end of q1 2017, company had a cash position of eur 349.9 million compared to eur 359.5 million.For financial year 2017, morphosys continues to expect group revenues in range of eur 46 to 51 million.Confirmed its guidance for earnings before interest and taxes (ebit) of eur -75 to -85 million.  Full Article

Morphosys chief scientific officer takes temporary leave
Thursday, 23 Mar 2017 02:30am EDT 

Morphosys AG : Says CSO Marlies Sproll takes temporary leave, Markus Enzelberger to serve as interim CSO .Says she continues to be a member of executive board and will return to her CSO role as soon as circumstances will allow.  Full Article

Morphosys reports smaller than expected 2016 EBIT loss
Thursday, 9 Mar 2017 01:00am EST 

Morphosys AG : Financial guidance for 2016 met in full . Group revenues of eur 49.7 million (guidance: eur 47 to 52 million) . EBIT of eur -59.9 million (guidance: eur -58 to -68 million) . Strong cash position of eur 359.5 million at year-end (dec. 31, 2015: eur 298.4 million) .In 2016, consolidated net result amounted to eur -60.4 million (2015: eur 14.9 million).  Full Article

Morphosys sees FY 2016 revenue eur 47-52 million
Monday, 1 Aug 2016 01:07am EDT 

Morphosys Ag :Sees fy 2016 revenue eur 47 million to eur 52 million.  Full Article

Morphosys H1 EBIT at -19.2 mln eur
Monday, 1 Aug 2016 01:07am EDT 

Morphosys Ag : Says group revenue in first half of 2016 totaled eur 24.3 million and EBIT amounted to eur -19.2 million . Says group's liquidity position on june 30, 2016 equaled eur 279.7 million (December 31, 2015: eur 298.4 million) .Says company confirms its 2016 guidance for revenue in range of eur 47 million to eur 52 million and EBIT between eur -58 million and eur -68 million..  Full Article

Morphosys AG confirms FY 2016 guidance
Tuesday, 3 May 2016 01:00am EDT 

Morphosys AG:Says confirmed its 2016 financial year guidance for revenue in range of 47 million euros to 52 million euros and EBIT loss in range of 58 million euros to 68 million euros.FY 2016 revenue estimate 49.01 million euros - Thomson Reuters I/B/E/S.FY 2016 EBIT loss estimate 66.5 million euros - Thomson Reuters I/B/E/S.  Full Article

Morphosys says Phase 2b/3 of bimagrumab fails to reach goal
Thursday, 21 Apr 2016 01:59am EDT 

Morphosys AG:Partner Novartis has confirmed that a phase 2b/3 study of bimagrumab did not meet its primary endpoint.Data are currently being reviewed and will inform decisions on bimagrumab development program.Ongoing clinical trials are not being discontinued at this time.  Full Article

Galapagos and Morphosys initiate phase 1 study in joint antibody program MOR106
Thursday, 7 Apr 2016 10:05am EDT 

Galapagos NV:Galapagos and Morphosys MORG.DE initiate phase 1 study in joint antibody program MOR106.Primary objective of phase 1 study is to evaluate safety and tolerability of single doses of MOR106.Topline results of complete study are expected in second half of 2017.  Full Article

Morphosys initiates phase 2 combination trial of MOR208 and Lenalidomide in patients with relapsed or refractory diffuse large B Cell lymphoma
Wednesday, 6 Apr 2016 01:31am EDT 

Morphosys AG:Initiates phase 2 combination trial of MOR208 and Lenalidomide in patients with relapsed or refractory diffuse large B Cell lymphoma.  Full Article

More From Around the Web

BRIEF-Morphosys: Janssen updates on development of guselkumab

* ANNOUNCES THAT ITS LICENSEE JANSSEN REPORTED UPDATES ON DEVELOPMENT OF GUSELKUMAB